Clinical Trial Search

Primary: The Primary Endpoint Will be in Hospital Major Bleed as Defined by the Study Protocol, Assessed at Three Time Points: After Study Drug Administration, But Prior to…

Primary: Number of Participants With a Response (Complete Remissions (CR), Complete Remissions With Incomplete Platelet Recovery [CRp] and Partial Responses) — 1; 1; 0 participants

Primary: Total Pain Relief Based on Numerical Rating Scale (NRS) Score — 17.7; 12.4; 13.3 Units on a scale — p=<0.0001

Primary: Change From Baseline to Week 24 in Muscle Strength — 0.4 score on a scale

Primary: Amount ($) Earned for Targeted Prosocial and Healthy Behaviors — 16.21 $ Vouchers

Primary: Percent Change in Bone Mineral Density — 0.1; -2; 0.2; -2.2 Percent Change — p=0.004

Primary: Cecal Intubation Time

Primary: Number of Participants With Plasma Uric Acid (UA) Response — 39; 34 participants

Primary: Percentage of Participants With at Least 30 Percent Reduction From Baseline in Blood Phenylalanine (Phe) Level — 75 Percentage of participants

Primary: Percentage Surface Microhardness Recovery (%SMHR) Dose Response Relationship — 30.89; 28.71; 25.28; 21.03 %SMHR — p=<0.0001

Primary: Change in Glycosylated Hemoglobin (HbA1c) — 8.13; 8.19; -1.00; -1.05 percentage — p=0.4602

Primary: Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 12 Weeks. — 0.134; 0.293; 0.262 Liter — p=0.0005

Primary: Quality of Life, Physical Health Composite — 46.8; 46.4; 47.2 units on a scale

Primary: Clearance of Sugammadex by Dialysis as Measured by the Reduction Ratio (RR) — 0.687; 0.566; 0.516; 0.532 Reduction Ratio

Primary: Korean Version of the Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (K-ARS) Score — 11.78 Units on a scale